Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 11/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2411062 | 0.88 | POLB (0.41) | TP53LMNAMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL2411257 | 0.87 | POLB (0.40) | TP53LMNAMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL14106702 | 0.86 | TP53 (0.47) | TP53LMNAMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL14451694 | 0.85 | POLB (0.40) | TP53LMNAMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL2413981 | 0.85 | POLB (0.41) | TP53LMNAMAPTKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2416966 | 0.84 | POLB (0.40) | TP53LMNAMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL2413348 | 0.84 | TP53 (0.43) | TP53LMNAMAPTKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2417800 | 0.84 | POLB (0.41) | TP53LMNAMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL2411290 | 0.82 | POLB (0.42) | TP53LMNAMAPTKDM4ESMN1; SMN2 | |
| SCHEMBL2408257 | 0.82 | POLB (0.43) | TP53LMNAMAPTKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| US-8026370-B2 | Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | MITSUBISHI PHAMA CORPORATION (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | MITSUBISHI PHAMA CORPORATION (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1816128-A1 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-08-08 | — | — | EP | disclosed |
| EP-1816128-A1 | CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167307-A1 | Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof | PPARA, PPARD, PPARG | TP53 2553/4885LMNA 3376/4885MAPT 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.